Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Antibody-drug Conjugate/ADC Related >> Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for Antibody Drug Conjugates (ADC) comprise of an active cytotoxic drug and an appropriate linker. The Drug-Linker Conjugates can expand the utility of monoclonal antibody (mAbs) and improve their potency and effectiveness. The site-specific conjugations of Drug-Linker to an antibody may involve genetic engineering of the mAb to introduce discrete, available cysteines or non-natural amino acids with an orthogonally-reactive functional group handle. These site-specific approaches not only increase the homogeneity of ADCs but also enable novel bio-orthogonal chemistries that utilize reactive moieties other than thiol or amine. The cytotoxic drug, monomethyl auristatin E (MMAE), is conjugated to the three trastuzumab variants using a protease cleavable linker and shows in vivo therapeutic efficacy.

Targets for  Drug-Linker Conjugates for ADC

Products for  Drug-Linker Conjugates for ADC

  1. Cat.No. Product Name Information
  2. GC64069 (Rac)-Lys-SMCC-DM1 (Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1. Lys-SMCC-DM1 is a linker-payload component that has the potential to inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. (Rac)-Lys-SMCC-DM1 Chemical Structure
  3. GC34122 Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) (LCB14-0602) is a drug-linker conjugate for ADC. Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) Chemical Structure
  4. GC65578 Aminobenzenesulfonic auristatin E TFA Aminobenzenesulfonic auristatin E TFA is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic. Aminobenzenesulfonic auristatin E TFA Chemical Structure
  5. GC67877 Aminobenzenesulfonic auristatin E-d8 Aminobenzenesulfonic auristatin E-d8 Chemical Structure
  6. GC64830 Azido-PEG4-Val-Cit-PAB-MMAE Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH. Azido-PEG4-Val-Cit-PAB-MMAE Chemical Structure
  7. GC43277 Cl2-SN-38

    CL2-SN-38 is a cleavable linker-based Drug-Linker conjugate, it can conjugate with the anti-Trop-2-humanized antibody hRS7. CL2-SN-38 can be used for the reasearch of cancer.

     Cl2-SN-38 Chemical Structure
  8. GC35789 Cys-mcMMAD Cys-mcMMAD is a drug-linker conjugate for ADC. MMAD is a potent tubulin inhibitor. Cys-mcMMAD Chemical Structure
  9. GC34357 DBCO-(PEG)3-VC-PAB-MMAE DBCO-(PEG)3-VC-PAB-MMAE is a drug-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer. DBCO-(PEG)3-VC-PAB-MMAE Chemical Structure
  10. GC67932 DBCO-PEG4-GGFG-Exatecan DBCO-PEG4-GGFG-Exatecan Chemical Structure
  11. GC62261 DBCO-PEG4-MMAF

    DBCO-PEG4-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4.

     DBCO-PEG4-MMAF Chemical Structure
  12. GC64489 DBCO-PEG4-VA-PBD

    DBCO-PEG4-VA-PBD is a drug-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via DBCO-PEG4-VA.

     DBCO-PEG4-VA-PBD Chemical Structure
  13. GC65926 DBCO-PEG4-Val-Cit-PAB-MMAF DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs). DBCO-PEG4-Val-Cit-PAB-MMAF Chemical Structure
  14. GC63504 DBCO-PEG4-VC-PAB-DMEA-PNU-159682 DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for?ADC, consists the ADC linker DBCO-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682. DBCO-PEG4-VC-PAB-DMEA-PNU-159682 Chemical Structure
  15. GC68145 DBCO-PEG4-VC-PAB-MMAE DBCO-PEG4-VC-PAB-MMAE Chemical Structure
  16. GC65359 DBM-MMAF DBM-MMAF is a drug-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody drug conjugate (ADC). DBM-MMAF Chemical Structure
  17. GC35840 Deruxtecan Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and amaleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402. Deruxtecan Chemical Structure
  18. GC67872 Deruxtecan analog 2 Deruxtecan analog 2 Chemical Structure
  19. GC38479 DM4-SMCC DM4-SMCC is a drug-linker conjugate for ADC with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker. DM4-SMCC Chemical Structure
  20. GC38460 DM4-SPDP DM4-SPDP is a drug-linker conjugate composed of a potent antitubulin agent DM4 and a linker SMCC to make antibody drug conjugate. SPDP is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls. DM4-SPDP Chemical Structure
  21. GC15250 DOXO-EMCH Prodrug of doxorubicin DOXO-EMCH Chemical Structure
  22. GC62134 Doxorubicin-SMCC Doxorubicin-SMCC is a drug-linker conjugate for ADC. Doxorubicin-SMCC contains a non-cleavable ADC linker and a DNA topoisomerase II inhibitor Doxorubicin. Doxorubicin-SMCC Chemical Structure
  23. GC38507 Fmoc-Val-Cit-PAB-Duocarmycin TM Fmoc-Val-Cit-PAB-Duocarmycin TM is a drug-linker conjugate for ADC by using the antitumor antibiotic, Duocarmycin TM, linked via Fmoc-Val-Cit-PAB. Fmoc-Val-Cit-PAB-Duocarmycin TM Chemical Structure
  24. GC33032 Fmoc-Val-Cit-PAB-MMAE Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Fmoc-Val-Cit-PAB-MMAE Chemical Structure
  25. GC60870 Gemcitabine-O-Si(di-iso)-O-Mc Gemcitabine-O-Si(di-iso)-O-Mc is a drug-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent;), linked via the ADC linker. Gemcitabine-O-Si(di-iso)-O-Mc Chemical Structure
  26. GC62686 Gly3-VC-PAB-MMAE Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs). Gly3-VC-PAB-MMAE Chemical Structure
  27. GC33500 Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) (Lys-Nε-MCC-DM1) is a linker-payload component that has the potential to inhibit tubulin polymerization.Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is the active metabolite of T-DM1. T-DM1 is a human epidermal growth factor receptor 2 (HER2)-targeting ADC with a tubulin polymerization inhibitor DM1. Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) Chemical Structure
  28. GC63057 Mal-(CH2)5-Val-Cit-PAB-Eribulin Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB. Mal-(CH2)5-Val-Cit-PAB-Eribulin Chemical Structure
  29. GC64309 Mal-C6-α-Amanitin Mal-C6-α-Amanitin is a drug-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6. Mal-C6-α-Amanitin Chemical Structure
  30. GC34379 MAL-di-EG-Val-Cit-PAB-MMAE MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). MAL-di-EG-Val-Cit-PAB-MMAE Chemical Structure
  31. GC36531 MAL-di-EG-Val-Cit-PAB-MMAF MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F). MAL-di-EG-Val-Cit-PAB-MMAF Chemical Structure
  32. GC36533 Mal-PEG2-VCP-Eribulin Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates. Mal-PEG2-VCP-Eribulin Chemical Structure
  33. GC64801 Mal-PEG4-VA-PBD Mal-PEG4-VA-PBD is a drug-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via Mal-PEG4-VA. Mal-PEG4-VA-PBD Chemical Structure
  34. GC63503 Mal-PEG4-VC-PAB-DMEA-PNU-159682 Mal-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682. Mal-PEG4-VC-PAB-DMEA-PNU-159682 Chemical Structure
  35. GC64443 Mal-PEG8-Val-Cit-PAB-MMAE Mal-PEG8-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Mal-PEG8-Val-Cit-PAB-MMAE contains a cleavable ADC linker and a potent tubulin inhibitor MMAE. Mal-PEG8-Val-Cit-PAB-MMAE Chemical Structure
  36. GC64850 Mal-Phe-C4-VC-PAB-MMAE Mal-Phe-C4-VC-PAB-MMAE is made by MMAE conjugated to Mal-Phe-C4-VC-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate. Mal-Phe-C4-VC-PAB-MMAE Chemical Structure
  37. GC63388 Mal-VC-PAB-DM1 Mal-VC-PAB-DM1 is a drug-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB . Mal-VC-PAB-DM1 Chemical Structure
  38. GC66374 MC-betaglucuronide-MMAE-1 MC-betaglucuronide-MMAE-1 is a drug-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide. MC-betaglucuronide-MMAE-1 Chemical Structure
  39. GC65079 MC-DOXHZN hydrochloride MC-DOXHZN ((E/Z)-Aldoxorubicin) hydrochloride is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties. MC-DOXHZN hydrochloride Chemical Structure
  40. GC67885 MC-Gly-Gly-Phe-Gly-amide-cyclopropanol-amide-Exatecan MC-Gly-Gly-Phe-Gly-amide-cyclopropanol-amide-Exatecan Chemical Structure
  41. GC68290 MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan Chemical Structure
  42. GC36560 Mc-MMAD Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a drug-linker conjugate for ADC. Mc-MMAD Chemical Structure
  43. GC36561 Mc-MMAE Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a drug-linker conjugate for ADC. Mc-MMAE Chemical Structure
  44. GC36563 MC-Sq-Cit-PAB-Dolastatin10 MC-Sq-Cit-PAB-Dolastatin10 is a drug-linker conjugate for ADC with potent antitumor activity by using Dolastatin10 (a tubulin polymerization inhibitor), linked via the ADC linker MC-Sq-Cit-PAB. MC-Sq-Cit-PAB-Dolastatin10 Chemical Structure
  45. GC36564 MC-Sq-Cit-PAB-Gefitinib MC-Sq-Cit-PAB-Gefitinib is a drug-linker conjugate for ADC with potent antitumor activity by using Gefitinib (an EGFR tyrosine kinase inhibitor), linked via the ADC linker MC-Sq-Cit-PAB. MC-Sq-Cit-PAB-Gefitinib Chemical Structure
  46. GC67812 MC-VA-PAB-Exatecan MC-VA-PAB-Exatecan Chemical Structure
  47. GC65109 MC-VA-PABC-MMAE MC-VA-PABC-MMAE is a drug-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE. MC-VA-PABC-MMAE Chemical Structure
  48. GC39403 MC-Val-Ala-PBD MC-Val-Ala-PBD is a drug-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala. MC-Val-Ala-PBD Chemical Structure
  49. GC36567 MC-Val-Cit-PAB-Auristatin E MC-Val-Cit-PAB-Auristatin E is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB. MC-Val-Cit-PAB-Auristatin E Chemical Structure
  50. GC36568 MC-Val-Cit-PAB-carfilzomib MC-Val-Cit-PAB-carfilzomib is a drug-linker conjugate for ADC with potent antitumor activity by using carfilzomib (an irreversible proteasome inhibitor), linked via the ADC linker MC-Val-Cit-PAB. MC-Val-Cit-PAB-carfilzomib Chemical Structure
  51. GC36569 MC-Val-Cit-PAB-clindamycin MC-Val-Cit-PAB-clindamycin is a drug-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB. MC-Val-Cit-PAB-clindamycin Chemical Structure
  52. GC36570 MC-Val-Cit-PAB-dimethylDNA31 MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus. MC-Val-Cit-PAB-dimethylDNA31 Chemical Structure
  53. GC36571 MC-Val-Cit-PAB-duocarmycin MC-Val-Cit-PAB-duocarmycin is a drug-linker conjugate for ADC with potent antitumor activity by using Duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB. MC-Val-Cit-PAB-duocarmycin Chemical Structure
  54. GC64817 MC-Val-Cit-PAB-DX8951 MC-Val-Cit-PAB-DX8951 (MC-Val-Cit-PAB-DX8951) is a drug-linker conjugate for ADC. MC-Val-Cit-PAB-DX8951 is composed of a DNA topoisomerase I DX-8951 and a cathepsin cleavable ADC linker. MC-Val-Cit-PAB-DX8951 Chemical Structure
  55. GC36572 MC-Val-Cit-PAB-indibulin MC-Val-Cit-PAB-Indibulin is a drug-linker conjugate for ADC with potent antitumor activity by using Indibulin (an orally applicable inhibitor of tubulin assembly), linked via the ADC linker MC-Val-Cit-PAB. MC-Val-Cit-PAB-indibulin Chemical Structure
  56. GC36573 MC-Val-Cit-PAB-retapamulin MC-Val-Cit-PAB-Retapamulin is a drug-linker conjugate for ADC with potent antitumor activity by using Retapamulin (a ribosome inhibitor), linked via the ADC linker MC-Val-Cit-PAB. MC-Val-Cit-PAB-retapamulin Chemical Structure
  57. GC36574 MC-Val-Cit-PAB-rifabutin MC-Val-Cit-PAB-rifabutin is a drug-linker conjugate for ADC with potent antitumor activity by using rifabutin (an DNA-dependent RNA polymerase inhibitor), linked via the ADC linker MC-Val-Cit-PAB. MC-Val-Cit-PAB-rifabutin Chemical Structure
  58. GC36575 MC-Val-Cit-PAB-tubulysin5a MC-Val-Cit-PAB-tubulysin5a is a drug-linker conjugate for ADC with potent antitumor activity by using Tubulysin M (a tubulin inhibitor), linked via the ADC linker MC-VC(S)-PABQ. MC-Val-Cit-PAB-tubulysin5a is effective against multidrug-resistant lymphoma cell lines and tumors. MC-Val-Cit-PAB-tubulysin5a Chemical Structure
  59. GC36576 MC-Val-Cit-PAB-vinblastine MC-Val-Cit-PAB-vinblastine is a drug-linker conjugate for ADC with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB. MC-Val-Cit-PAB-vinblastine Chemical Structure
  60. GC38481 MC-VC-PABC-Aur0101 MC-VC-PABC-Aur0101 is a drug-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC. MC-VC-PABC-Aur0101 Chemical Structure
  61. GC36577 MC-VC-PABC-DNA31 MC-VC-PABC-DNA31 is a drug-linker conjugate for ADC with potent antitumor activity by using DNA31 (a potent RNA polymerase inhibitor), linked via the ADC linker MC-VC-PABC. MC-VC-PABC-DNA31 Chemical Structure
  62. GC62647 MCC-DM1 MCC-DM1 is a drug-Linker Conjugates for ADC such ad Anti-CD22-MCC-DM1. MCC-DM1 Chemical Structure
  63. GC34068 McMMAF (Maleimidocaproyl monomethylauristatin F) McMMAF (Maleimidocaproyl monomethylauristatin F) is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor. McMMAF (Maleimidocaproyl monomethylauristatin F) Chemical Structure
  64. GC33161 mDPR-Val-Cit-PAB-MMAE mDPR-Val-Cit-PAB-MMAE Chemical Structure
  65. GC62655 MMAE-SMCC MMAE-SMCC is a drug-linker conjugate for ADC. MMAE-SMCC is composed of a potent?mitotic and a tubulin inhibitor MMAE and a linker SMCC to make antibody drug conjugate. MMAE-SMCC Chemical Structure
  66. GC62195 MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a Camptothecin-linker compound extracted from patent WO2019195665A1, example 4-1. MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a drug-linker conjugate for antibody-drug conjugate (ADC). MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT Chemical Structure
  67. GC34378 N3-PEG3-vc-PAB-MMAE N3-PEG3-vc-PAB-MMAE is a synthesized drug-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity. N3-PEG3-vc-PAB-MMAE Chemical Structure
  68. GC68412 NAMPT inhibitor-linker 1 NAMPT inhibitor-linker 1 Chemical Structure
  69. GC36748 Nitro-PDS-Tubulysin M Nitro-PDS-Tubulysin M is a drug-linker conjugate for ADC with potent antitumor activity by using Tubulysin M (a tubulin polymerization inhibitor), linked via the ADC linker Nitro-PDS. Nitro-PDS-Tubulysin M Chemical Structure
  70. GC32725 SMCC-DM1 (DM1-SMCC) SMCC-DM1 (DM1-SMCC) (DM1-SMCC) is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody drug conjugate (ADC). SMCC-DM1 (DM1-SMCC) Chemical Structure
  71. GC69916 SN38-COOH

    SN38-COOH can be used to synthesize antibody-active molecule conjugates (ADCs). SN-38 is the active metabolite of topoisomerase I inhibitor irinotecan. SN-38 inhibits DNA and RNA synthesis.

     SN38-COOH Chemical Structure
  72. GC33619 SPB SPB is a drug-linker conjugate for ADC with potent anti-inflammatory activity by using Xanthotoxol, linked via the ADC linker. SPB Chemical Structure
  73. GC32982 SPDB-DM4 SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity. SPDB-DM4 Chemical Structure
  74. GC38478 SPP-DM1 SPP-DM1 is a drug-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP. SPP-DM1 Chemical Structure
  75. GC37682 ST8154AA1 ST8154AA1 Chemical Structure
  76. GC37683 ST8155AA1 ST8155AA1 Chemical Structure
  77. GC69960 STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA

    STING agonist-20-Ala-amide-PEG2-C2-NH2 (Compound 30b) TFA is a scaffold containing a stimulator of the interferon gene (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used for synthesizing immune-stimulating antibody conjugates (ISACs). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can also be used in cancer research.

     STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA Chemical Structure
  78. GC33040 sulfo-SPDB-DM4

    sulfo-SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.

     sulfo-SPDB-DM4 Chemical Structure
  79. GC63859 SuO-Glu-Val-Cit-PAB-MMAE SuO-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs). SuO-Glu-Val-Cit-PAB-MMAE Chemical Structure
  80. GC34380 SuO-Val-Cit-PAB-MMAE SuO-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB. SuO-Val-Cit-PAB-MMAE Chemical Structure
  81. GC34428 SW-163D-AcLysValCit-PABC-DMAE SW-163D-AcLysValCit-PABC-DMAE Chemical Structure
  82. GC67868 TCO-PEG4-VC-PAB-MMAE TCO-PEG4-VC-PAB-MMAE Chemical Structure
  83. GC63216 Tesirine Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity. Tesirine Chemical Structure
  84. GC67500 Thalidomide-NH-PEG7 Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate for ADC. Thalidomide-NH-PEG7 can be connected to the ligand for protein by a linker to form PROTAC iRucaparib-AP6, a highly specific PARP1 degrader. Thalidomide-NH-PEG7 Chemical Structure
  85. GC32799 Val-Cit-PAB-MMAE Val-Cit-PAB-MMAE is a?drug-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE. MMAE?a potent?mitotic?inhibitor by inhibiting tubulin polymerization. Val-Cit-PAB-MMAE Chemical Structure
  86. GC67887 Val-Cit-PAB-MMAF sodium Val-Cit-PAB-MMAF sodium Chemical Structure
  87. GC38480 Vat-Cit-PAB-Monomethyl Dolastatin 10 Vat-Cit-PAB-Monomethyl Dolastatin 10 is a drug-linker conjugate for ADC with potent antitumor activity by using Monomethyl Dolastatin 10 (a potent tubulin inhibitor), linked via the ADC linker Vat-Cit-PAB. Vat-Cit-PAB-Monomethyl Dolastatin 10 Chemical Structure
  88. GC37890 Vc-MMAD Vc-MMAD consists the ADCs linker (Val-Cit) and potent tubulin inhibitor (MMAD). Vc-MMAD is a drug-linker conjugate for ADC. Vc-MMAD Chemical Structure
  89. GC63356 Vc-seco-DUBA Vc-seco-DUBA (SYD985) is a drug-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco. Vc-seco-DUBA Chemical Structure
  90. GC37891 VcMMAE VcMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). VcMMAE Chemical Structure
  91. GC37892 VCP-Eribulin VCP-Eribulin consists the ADCs linker (VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. VCP-Eribulin is an Eribulin-based drug for antibody conjugates. VCP-Eribulin Chemical Structure

90 Item(s)

per page

Set Descending Direction